Karyopharm Therapeutics (KPTI) News Today $0.66 -0.04 (-5.47%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period What is HC Wainwright's Estimate for KPTI FY2024 Earnings?January 19 at 2:13 AM | americanbankingnews.comHC Wainwright Issues Pessimistic Outlook for KPTI EarningsKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Stock analysts at HC Wainwright cut their FY2024 earnings estimates for Karyopharm Therapeutics in a research note issued to investors on Wednesday, January 15th. HC Wainwright analyst E. White now anticipates that the company will post eJanuary 17, 2025 | marketbeat.comEdward White Recommends ‘Buy’ on Karyopharm Therapeutics Amid Promising Outlook and Strategic DevelopmentsJanuary 15, 2025 | markets.businessinsider.comKaryopharm Therapeutics' (KPTI) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday.January 15, 2025 | marketbeat.comJane Street Group LLC Has $170,000 Stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI)Jane Street Group LLC trimmed its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 86.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 204,750 shares of the company's stock after selliJanuary 14, 2025 | marketbeat.comKaryopharm Therapeutics Expects Q4 Revenues Of $30 MlnJanuary 13, 2025 | markets.businessinsider.comKaryopharm Announces Preliminary Unaudited 2024 Revenue and 2025 ObjectivesJanuary 13, 2025 | prnewswire.comBarclays PLC Has $79,000 Stock Holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI)Barclays PLC lowered its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 89.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 95,767 shares of the company's stock afterJanuary 10, 2025 | marketbeat.comWhy Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media?January 7, 2025 | msn.comKaryopharm Therapeutics Appoints Lori Macomber As CFOJanuary 2, 2025 | markets.businessinsider.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 2, 2025 | prnewswire.comKaryopharm Announces the Appointment of Lori Macomber as Chief Financial OfficerJanuary 2, 2025 | prnewswire.comKaryopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Fifty Day Moving Average - What's Next?Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 50 Day Moving Average - Here's WhyDecember 31, 2024 | marketbeat.comKaryopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate CommunicationsDecember 9, 2024 | prnewswire.comKaryopharm Therapeutics Provides Endometrial Cancer Program UpdateDecember 3, 2024 | prnewswire.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Large Growth in Short InterestKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 18,930,000 shares, a growth of 7.0% from the October 31st total of 17,690,000 shares. Based on an average trading volume of 747,500 shares, the short-interest ratio is presently 25.3 days.December 3, 2024 | marketbeat.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 2, 2024 | prnewswire.comKaryopharm Therapeutics IncNovember 28, 2024 | money.usnews.comKaryopharm to Participate at the Piper Sandler 36th Annual Healthcare ConferenceNovember 25, 2024 | prnewswire.comKaryopharm Therapeutics (NASDAQ:KPTI) Cut to Hold at StockNews.comStockNews.com downgraded shares of Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday.November 22, 2024 | marketbeat.comKaryopharm appoints Kristin Abate as Chief Accounting OfficerNovember 21, 2024 | markets.businessinsider.comKaryopharm Therapeutics Appoints New Chief Accounting OfficerNovember 21, 2024 | markets.businessinsider.comKaryopharm Therapeutics Announces the Appointment of Chief Accounting OfficerNovember 20, 2024 | prnewswire.comKaryopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and ExpositionNovember 18, 2024 | prnewswire.comGSA Capital Partners LLP Purchases 792,283 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI)GSA Capital Partners LLP increased its holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 80.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,775,700 shares of the company's stockNovember 14, 2024 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Stock Rating Upgraded by StockNews.comStockNews.com upgraded shares of Karyopharm Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday.November 14, 2024 | marketbeat.comStrategic Clinical Advances and Revenue Growth Drive Buy Rating for Karyopharm TherapeuticsNovember 9, 2024 | markets.businessinsider.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?November 8, 2024 | finance.yahoo.comLeerink Partnrs Has Optimistic Outlook of KPTI Q4 EarningsKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Equities researchers at Leerink Partnrs boosted their Q4 2024 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a report released on Wednesday, November 6th. Leerink Partnrs analyst J. Chang now anticipates thatNovember 8, 2024 | marketbeat.comFY2024 Earnings Forecast for KPTI Issued By HC WainwrightKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Investment analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for Karyopharm Therapeutics in a note issued to investors on Tuesday, November 5th. HC Wainwright analyst E. White now expects that the company wNovember 8, 2024 | marketbeat.comKaryopharm Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 6, 2024 | finance.yahoo.comKaryopharm price target raised to $5 from $4 at Piper SandlerNovember 6, 2024 | markets.businessinsider.comRBC Capital Sticks to Its Buy Rating for Karyopharm Therapeutics (KPTI)November 6, 2024 | markets.businessinsider.comPiper Sandler Raises Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $5.00Piper Sandler increased their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an "overweight" rating in a research report on Wednesday.November 6, 2024 | marketbeat.comKaryopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...November 6, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc. Reports Q3 2024 EarningsNovember 6, 2024 | markets.businessinsider.comKaryopharm Therapeutics: Strong Demand and Strategic Initiatives Justify Buy RatingNovember 6, 2024 | markets.businessinsider.comKaryopharm Therapeutics (KPTI) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | msn.comKaryopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comAntengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024November 5, 2024 | prnewswire.comKaryopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNovember 5, 2024 | prnewswire.comKaryopharm changes endpoint in Phase 3 trial of selinexor in myelofibrosisNovember 1, 2024 | markets.businessinsider.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | prnewswire.comKaryopharm Therapeutics (KPTI) to Release Earnings on TuesdayKaryopharm Therapeutics (NASDAQ:KPTI) will be releasing earnings before the market opens on Tuesday, November 5, Zacks reports.November 1, 2024 | marketbeat.comKaryopharm Therapeutics' (KPTI) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a research note on Friday.November 1, 2024 | marketbeat.comPositive Developments and FDA Agreement Boost Karyopharm’s Buy RatingNovember 1, 2024 | markets.businessinsider.comKaryopharm to Report Third Quarter 2024 Financial Results on November 5, 2024October 31, 2024 | prnewswire.comKaryopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in MyelofibrosisOctober 31, 2024 | prnewswire.comKaryopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024October 30, 2024 | prnewswire.comKaryopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below 200-Day Moving Average - Here's What HappenedKaryopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below 200-Day Moving Average - Here's WhyOctober 30, 2024 | marketbeat.com Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address KPTI Media Mentions By Week KPTI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KPTI News Sentiment▼0.020.46▲Average Medical News Sentiment KPTI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KPTI Articles This Week▼93▲KPTI Articles Average Week Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Neumora Therapeutics News Today MBX Biosciences News Today Precigen News Today Olema Pharmaceuticals News Today Corvus Pharmaceuticals News Today Contineum Therapeutics News Today Chimerix News Today LifeVantage News Today enGene News Today Taysha Gene Therapies News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KPTI) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KPTI Stock Alerts